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Dex-CsDH randomised, placebo-
controlled trial of dexamethasone 
for chronic subdural haematoma: 
report of the internal pilot phase
ellie edlmann  1,2, eric p. thelin  1,3, Karen Caldwell2, Carole turner2, peter Whitfield4, 
Diederik Bulters  5, patrick Holton5, Nigel suttner6, Kevin owusu-Agyemang6, Yahia Z. Al-
tamimi7, Daniel Gatt7, simon thomson8, Ian A. Anderson8, oliver Richards8, Monica Gherle4, 
emma toman9, Dipankar Nandi10, phillip Kane11, Beatrice pantaleo12, Carol Davis-Wilkie12, 
silvia tarantino2, Garry Barton13, Hani J. Marcus  10, Aswin Chari14, Antonio Belli15, 
simon Bond12,16, Rafael Gafoor12, sarah Dawson12,16, Lynne Whitehead17, paul Brennan18, 
Ian Wilkinson12, Angelos G Kolias  1,2, peter J. A. Hutchinson1,2 & Dex-CsDH trial 
collaborative and BNtRC collaborative*
the Dex-CsDH trial is a randomised, double-blind, placebo-controlled trial of dexamethasone for 
patients with a symptomatic chronic subdural haematoma. the trial commenced with an internal 
pilot, whose primary objective was to assess the feasibility of multi-centre recruitment. primary 
outcome data collection and safety were also assessed, whilst maintaining blinding. We aimed to 
recruit 100 patients from United Kingdom Neurosurgical Units within 12 months. Trial participants were 
randomised to a 2-week course of dexamethasone or placebo in addition to receiving standard care 
(which could include surgery). The primary outcome measure of the trial is the modified Rankin Scale 
at 6 months. This pilot recruited ahead of target; 100 patients were recruited within nine months of 
commencement. 47% of screened patients consented to recruitment. The primary outcome measure 
was collected in 98% of patients. No safety concerns were raised by the independent data monitoring 
and ethics committee and only five patients were withdrawn from drug treatment. Pilot trial data can 
inform on the design and resource provision for substantive trials. this internal pilot was successful in 
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determining recruitment feasibility. excellent follow-up rates were achieved and exploratory outcome 
measures were added to increase the scientific value of the trial.
In a chronic subdural haematoma (CSDH), blood and fluid collect in the subdural space overlying the brain. It 
primarily affects elderly patients, many of whom have experienced a head trauma within the preceding weeks1. 
Recent literature suggests a critical role for inflammation in causing fluid and blood exudation from neovascu-
larised subdural membranes2. The application of steroids with their potent anti-inflammatory effect is therefore 
logical, and has shown potential in smaller, non-randomised studies3–9.
A multi-institutional group of clinicians and academics in the United Kingdom (UK) designed the Dex-CSDH 
trial to address a gap in evidence. The trial aims to investigate whether dexamethasone can improve the 6-month 
functional outcome of patients with symptomatic CSDH by reducing the rate of surgical intervention and recur-
rence. This paper describes the feasibility phase (internal pilot) of the Dex-CSDH trial.
The Consolidated Standards of Reporting Trials (CONSORT) recommendations have recently been extended 
to include pilot trials, all of which are addressed in this pilot (Fig. 1)10, alongside the standard CONSORT check-
list (see supplementary information). The data collected during internal pilots can be used in the final substantive 
trial analysis, and thus has remained blinded, but is still helpful for informing on the design of future pilot trials11.
primary pilot trial objective
The primary objective of the Dex-CSDH pilot Trial is to assess recruitment feasibility across UK neurosurgical 
units (NSU). Several factors may influence enrolment of patients and the following were considered in design of 
this trial;
 1. The UK has helped take a lead on improving research in neurosurgery, being 3rd in the world for publish-
ing neurosurgery randomised control trials (RCT) between 2000-201412. This has been a challenge due to 
historically low levels of neurosurgical RCTs which can result in deficient research infrastructure, training 
and experience13. Of 64 neurosurgical RCTs registered between 2000–2012, 17 (26.6%) were discontinued 
early, mainly because of insufficient patient recruitment14. To avoid this, focus on engagement of local 
research teams to maximise patient recruitment and retention is essential.
 2. Head trauma confers specific challenges to recruitment. The need for emergency intervention limits the 
time available for clinicians and patients to consider enrolment into clinical trials. Patients often lack 
capacity and the non-availability of a legal representative (e.g. next-of-kin (NOK)) can impede recruit-
ment. In 2006, the UK clinical trials directive amended the Medicines and Healthcare Products Regulatory 
Agency (MHRA) clinical trials guidelines regarding consent of incapacitated adults without an available 
NOK15. This now permits their enrolment in trials for urgent treatments, provided there is relevant ethics 
committee approval. The Dex-CSDH pilot trial has this approval in the form of “Independent Healthcare 
Provider (IHP) consent”.
 3. Finally, older patients are under-represented in medical research, even for pathologies or medicines 
most relevant to their age group16–18. As CSDH occurs almost exclusively in older patients, we aimed to 
demonstrate that the barriers to trial recruitment and follow-up can be overcome. Members from a local 
public involvement research group (INsPIRE) were involved in the trial design to help ensure it would be 
acceptable for our target patient group.
secondary pilot trial objectives. Our secondary objectives were to assess i) the feasibility of outcome 
measures ii) follow-up rates and iii) any early safety concerns.
Primary outcome data must be accurately and reliably collected to avoid bias from missing data. To optimise 
follow-up, postal and telephone questionnaires and involvement of the NOK were utilised.
An increased mortality in patients treated with steroids in the “Corticosteroid Randomisation After Significant 
Head injury” (CRASH) trial and the reported complication rate associated with steroid use in older patients, 
particularly those with co-morbidities, mandated a careful and thorough assessment of drug tolerability in this 
Figure 1. relevant methodological considerations in a pilot trial10.
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trial19–21. Conversely, successful and safe steroid use in older patients for treatment of polymyalgia rheumatica, 
temporal arteritis, chronic obstructive pulmonary disease and glioblastoma offers reassurance of beneficence22–25. 
Steroid side effects are generally dose and duration dependent23,26. Regimen optimisation is therefore important 
to minimise serious adverse events (SAEs) and maximise therapeutic benefit.
The internal pilot trial was designed using methodology concordant to the planned substantive trial, with the 
potential to make amendments if supported by the secondary objectives.
Methods
The Dex-CSDH pilot trial is a randomised, double-blind, placebo-controlled trial of a two-week course of dexa-
methasone for 100 adult patients with a symptomatic chronic subdural haematoma (see full protocol in supple-
mentary information). Patients were randomly assigned by an interactive web-based system to the intervention 
(dexamethasone) or control group (placebo). A 1:1 allocation as per a computer-generated randomisation sched-
ule stratified by site using permuted blocks of random sizes is employed.
Recruitment. In this pilot trial, we planned to recruit patients from up to 10 NSUs ranging in catchment 
population, research experience and resources, to reflect a realistic picture of multi-centre recruitment11. All 
NSUs had support from a local neurosurgical trainee acting as a co-principal investigator as part of the British 
Neurosurgical Trainee Collaborative (BNTRC)27. Hospital episode statistics (HES) indicate that a medium sized 
NSU admits 60–80 CSDH patients per year. Setting a conservative estimate, we predicted a recruitment rate of 
two patients per month for each NSU. We set an overall target of 100 patients to be recruited to the pilot within 
12 months.
Eligibility criteria and overall trial design were planned in a way that would maximise participation in order 
to support eventual translation of findings to as broad a population as possible (Tables 1 and 2). Informed con-
sent was obtained from the patient, NOK or IHP by an appropriately trained doctor or nurse identified on the 
delegation log.
primary outcome measure. The primary outcome measure was determined as the modified Rankin Scale 
(mRS) at six months’ post-randomisation, as it is a core instrument for measuring the degree of disability or 
dependence in daily activities of living (Fig. 2)28. It is an ordinal scale but dichotamised values of 0–3 (good out-
come) and 4–6 (poor outcome) have been used in previous CSDH research29,30. The final time-point of six months 
was selected so that most CSDH recurrences had occurred and been treated, and to permit adequate time for 
recovery and adaptation to disability31. The mRS is assessed by blinded research staff via telephone interviews or 
by the patient completing a structured postal questionnaire32.
secondary outcome measures. Secondary outcome measures are listed in Table 3. Amongst others, these 
included endpoints commonly used in the field of CSDH, such as re-operation, mortality and complications33.
Inclusion criteria Exclusion criteria
Adult patients (aged 18 and older) Patients who are already on steroids or with conditions where steroids are clearly contra-indicated
Symptomatic CSDH confirmed on cranial imaging 
(predominantly hypodense or isodense crescentic collection 
along the cerebral convexity, confirmed on CT).
Time interval from time to admission to NSU to first dose of trial 
medication exceeds 72 hours
Informed consent or IHP authorisation Previous enrolment in this trial for a prior episode or concurrent enrolment in any other trial of an IMP
Patients with CSF shunt or history of psychotic disorders
Severe lactose intolerance or known hypersensitivity to 
dexamethasone or other IMP excipients, or desire to avoid gelatin
Table 1. Dex-CSDH pilot trial inclusion and exclusion criteria. (CSDH = Chronic Subdural Haematoma, 
CSF = Cerebrospinal Fluid, CT = Computerised Tomography, IMP = Investigational Medicinal Product, 
NSU = Neurosurgical Unit, IHP = Independent Healthcare Provider).
Aid site engagement with recruitment Aid recruitment of eligible patients
Trainee Co-PI at all sites; to support PI with site set-up 
administration and encourage local recruitment
72-hour recruitment window; from admission to NSU, allowing 
sufficient time to contact relatives and avoid missing patients 
admitted at the weekend.
Face-to-face initiation; to engage maximum number of people in 
clinical team and answer questions/concerns before starting the trial
NOK and IHP consent; to allow inclusion of patients lacking 
capacity (which would be a large proportion with this condition) 
and those without a NOK available
Monthly screening logs; to monitor screening and allow early 
identification of any institutional reasons for screen failures
Medication diary; simple diary with dates and pictures to tick off 
each day, reminding patients what to take (as drug regime complex 
and elderly patients often already have polypharmacy)
Table 2. Trial design aspects to maximise broad recruitment. (IHP = Independent Healthcare Provider, 
NOK = Next-of-kin, NSU = Neurosurgical Unit, PI = Principal Investigator).
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Drug regimen and safety. The Dex-CSDH trial regimen was designed by incorporating a literature review 
(see Table 4) with the clinical expertise of the protocol development team including neurosurgeons, elderly care 
specialists and pharmacists. The regimen starts with a high dose (16 mg/day) and tapers down quickly to stop 
over 14 days, providing an average weekly dose of 62 mg dexamethasone. This is comparable to the average steroid 
doses reported in previous CSDH studies, and is at the lower end of course duration, to minimise complications 
from prolonged use. The drug is over-encapsulated so that dexamethasone is indistinguishable from placebo.
The pilot trial could potentially identify early safety concerns, therefore there was close monitoring of SAEs 
and adverse events of special interest (AESIs). The latter were adverse events we expected in relation to steroid use 
from our clinical experience in neurosurgery and included; hyperglycaemia requiring treatment or stopping of 
trial medication, new-onset diabetes, psychosis and gastric symptoms (e.g. dyspepsia, gastric ulcer).
progression from internal pilot to substantive trial. Progression criteria were determined prior to 
initiation of the pilot (Fig. 3). These were reviewed alongside the blinded pilot trial data by the trial steering 
committee (TSC), and the unblinded data by the independent data monitoring and ethics committee (IDMEC). 
Review of blinded pilot trial data was used to enable minor protocol modifications to assist conduct of the sub-
stantive trial (see results).
sample size calculation and statistical analysis for the substantive trial. The overall sample size 
of the substantive Dex-CSDH trial is 750 patients. An 8% increase in the rate of favourable outcome (mRS 0–3) 
at 6 months was considered a clinically important treatment effect. On the basis of the available literature, we 
estimated that 80–85% of the control group will have a favourable outcome3,29. Using a 2-sided test at the 5% 
significance level, a sample of 750 patients (allowing 15% loss to follow-up) will detect an absolute difference 
Figure 2. modified Rankin Scale28. Category 6 added to allow for mortality outcomes.
Outcome measures (protocol version 1.0) Changes following pilot trial
Primary outcome measure; mRS at 6 months Re-formatted, mRS adjudication and return window added (−4/+8 weeks)
Secondary outcome measures; Return windows added: 3 months (+/−8 weeks) 6 months (−4/+8 weeks)
No. of CSDH-related surgical interventions undertaken during 
the index admission and subsequent admissions in follow-up 
period
Unchanged
GCS at discharge from NSU and at 6 months Unchanged
mRS at discharge from NSU Re-formatted and mRS adjudication added
mRS at 3 months Re-formatted and mRS adjudication added
Barthel Index at discharge from NSU, 3 months and 6 months Unchanged
MoCA at discharge and clinical follow-up Removed
EQ-5D at discharge, 3 months and 6 months Unchanged
Length of stay in NSU and secondary care Unchanged
Discharge destination from NSU Unchanged
30-day and 6-month mortality Unchanged
Related complications Changed AESI/SAE collection process
Health economic analysis Unchanged
Exploratory outcome measures Added
Table 3. Trial outcome measures and changes made following completion of pilot. (AESI = Adverse Event 
of Special Interest, CSDH = Chronic Subdural Haematoma, Eq. 5D = EuroQol-5D, GCS = Glasgow Coma 
Scale, MoCA = Montreal Cognitive Assessment, mRS = modified Rankin Scale, NSU = Neurosurgical unit, 
SAE = Severe Adverse Event).
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of 8% with a power of 81–92%. The internal pilot data will be included in the substantive trial results, on an 
intention-to-treat analysis. Secondary endpoints will also be summarised and an economic analysis performed 
(see protocol for full details).
Results
primary objective: Recruitment. Pilot trial recruitment commenced in August 2015, five months later 
than the original anticipated start date of March 2015 (Fig. 4). A further six sites opened to recruitment over the 
subsequent eight months. The 100th patient was recruited within nine months of the August start date, easily sur-
passing the recruitment target rate and allowing progression onto the substantive trial which has now recruited 
653 patients to July 2018 (Table 5).
The time from research and development (R + D) first contact to site opening was an average of 5.7 months in 
the pilot trial (excluding the sponsor site which required a more rigorous opening procedure), and has increased 
to nine months for the substantive trial (see Table 5).
Anonymised patient screening logs were available from all pilot sites; 47% of patients screened were enrolled 
(Table 6). A reason for screening failure was provided in 92 out of the 114 pilot patients screened (81%). The most 
common reason was patient or NOK declining consent (42%), followed by patient co-morbidities (19%), current 
steroid use (13%), outside 72 hr recruitment window (9%), NOK unable to attend for consent (8%) and other 
reasons (9%).
secondary objectives: outcome measures, follow-up and safety. The outcome measures were com-
pleted centrally via postal or telephone questionnaire with few errors. The mRS questionnaire created several 
queries and the Montreal Cognitive Assessment (MoCA) was poorly completed therefore these two parts were 
reviewed for amendment (see changes to substantive trial protocol below). The remaining outcome measures 
were considered appropriate to the trial population and easy to collect.
On completion of the pilot, the first 31 patients had completed their primary outcome at six months and 55 
patients had met the secondary 3-month outcome time point (Table 7). Retention in the pilot trial was excellent 
with primary outcome data received from 100% of the 30 eligible patients (one patient withdrawn). In 5% of 
patients, data was missing at the secondary time-point of 3-months. At six months, nearly all patients were back 
at home, or else the General Practitioners (GP) was aware of the patient location, enabling improved follow-up 
at this later time point.
The outcome data was reviewed again when all 100 pilot patients had met their primary end-point at 6-months 
and was still collected for 100% of eligible patients (two patients withdrawn). The patterns of change in mRS from 
Paper (year)
Patient number
(follow-up)
Dex dosing schedule
(average weekly dose) Adverse events Outcome
Dex-CSDH pilot trial 100 dex and placebo(6 M)
8 mg BD for 3D, 6 mg BD for 3D, 4 mg BD for 
3D, 2 mg BD for 3D, 2 mg OD for 2D (62 mg) See Table 8 for pilot adverse events See Fig. 5 for pilot outcomes.
Bender (1974)8 37(mean 2.5 years)
60–120 mg prednisolone for average of 21 days
(Equivalent 70–140 mg) None reported.
Reduced bed rest & hospitalisation. 
71% patients avoided surgery.
Sun
(2005)3
26 dex
69 dex & surgery
13 surgery
Dex alone: 16 mg daily for approx. 21 days.
(112 mg)
2/4 DM patients needed additional 
insulin, resolved on stopping 
treatment.
84% favourable outcome in dex alone. 
Recurrence 4% with dex versus 15% 
without.
Delgado-Lopez
(2009)9
101
(median 6 M)
12 mg daily, tapering by 1 mg every 3 days
(46.8 mg)
Hyperglycaemia (14.8%) and 
infections (9%), 1 gastric ulcer 
(<1%).
78.2% dex patients avoided surgery.
96% favourable outcome with dex.
Berghauser Pont
(2012)4
496
(3 M)
dex 16 mg daily starting median of 4 days pre-
op and then weaning
(unspecified).
Empyema 2.8%
DVT/PE 1.8%
Hyperglycaemia only whilst on dex.
Longer pre-operative dex dose 
associated with lower recurrence 
and no
increased morbidity.
Berghauser Pont 
(2012)5
5 studies with total 
520
Study 1–3 as per Bender, Delgado-Lopez, 
Sun2,7,8
Study 4: 16 mg/day tapering over 8wks.
Study 5: 0.5 mg/kg pred = 6 mg dex/day for 
4 wks.
Infections 9%
GI bleed <1% (2/520)
Hyperglycaemia 7.7–14.8% (higher 
with long-term use)
Good outcome in 83–100% with 
steroids and
64–92% surgery alone
Recurrence: 4–27.8% with steroids 
and 15–26.3% surgery alone.
Emich
(2014)52
820 dex and placebo
(24 weeks)
6 day course of dex from 16 mg/day to, 4 mg/
day.
(68 mg)
Trial on-going since 2014: no safety 
issues reported
Primary end-point will be re-
operation within 12 weeks.
Chan
(2015)53
122 dex & surgery
126 surgery alone
16 mg for 4D, 6 mg for 3D, 2 mg for 3D
(61.6 mg).
No increase in adverse events with 
dex
6.6% recurrence dex & surgery, 13.5% 
surgery only. 83–85% favourable 
outcome in both groups.
Thotakura (2015)7 26(mean 16.5 M)
12 mg/day for 3D, then tapered over 4 weeks
(27.5 mg)
1 hyperglycaemia
1 gastritis. 42% avoided surgery
Prudhomme (2016)54 20 dex or placebo (6 M) 12 mg/day for 21D,tapered over 7D (70.25 mg)
4 hyperglycaemia,
5 other SAEs Trial halted due to high SAE rate.
Qian
(2017)6
75 dex
167 no dex
4.5 mg TDS for 4D, weaned every 4D 
(155.13 mg)
5/13 DM patients with 
hyperglycaemia.
Recurrence 8% with dex, 19.8% 
without dex.
Table 4. Review of dexamethasone dosing schedules, adverse events and outcomes in the CSDH literature 
compared to Dex-CSDH pilot trial. (BD = twice a day, D = day, dex = dexamethasone, DM = Diabetes Mellitus, 
GI = Gastrointestinal, M = Month, OD = Once a Day, SAE = Serious Adverse Event, TDS = Three times a Day).
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data reviewed at the steering committe meeting following completion of the pilot  are summarised in Fig. 5. 
Collection rates of the secondary time-point of 3-months was slightly worse, with 11% of data missing.
An SAE was experienced in 10 (10%) of pilot trial patients, with one patient experiencing two SAEs (Table 8). 
Twelve patients (12%) experienced an AESI, with hyperglycaemia the most common event (Table 8). As only the 
IDMEC has access to unblinded data, it is not possible to currently state whether these AESIs occurred in patients 
receiving dexamethasone or placebo.
Overall, there was a 5% (5/100) withdrawal rate from the trial medication. Two patients withdrew because of 
hyperglycaemia. One patient withdrew following a stroke, after taking the trial medication for only one day. These 
three patients remained in the trial with regards to follow-up. Two further patients withdrew completely from the 
trial and all follow-up; one felt the tablets were too large and the other reported hallucinations after taking one 
dose (reported as AESI). Unblinded data was reviewed by the IDMEC and the compliance and safety profile of the 
trial medication was considered acceptable.
The TSC reviewed all pilot data and confirmed that as patient recruitment was feasible and there were no eth-
ical or safety concerns, the substantive trial should take place. Recommendations were made for minor protocol 
Figure 3. formal progression criteria for Dex-CSDH pilot trial.
Site
Date of 
local R + D 
Application
Months from 
R + D to site 
opening
Pilot: 
All pts 
(n)
Pilot: 
mean pts/
month (n)
ST: All pts 
to 19/7/18 
(n)
ST: mean 
pts/month 
(n)
Cambridge (Lead 
site) Jan 2014 19 75 8 243 6.75
*
Plymouth Mar 2015 7 5 0.7 32 0.9
Imperial Aug 2015 5 2 0.5 5 0.2
Southampton Sept 2015 4 13 3.3 74 2.4*
Middlesbrough Oct 2015 5 2 1 21 0.7
Sheffield Oct 2015 5 2 1 47 1.6*
Birmingham Aug 2015 8 1 1 23 0.8
Brighton Oct 2015 6 N/A N/A 21 0.8
Leeds Oct 2015 7 N/A N/A 38 1.4
Glasgow Oct 2015 7 N/A N/A 52 1.9*
Stoke Sept 2015 9 N/A N/A 20 0.8
Preston Sept 2015 11 N/A N/A 7 0.3
Aberdeen Nov 2015 9 N/A N/A 9 0.4
Edinburgh Nov 2015 11 N/A N/A 11 0.5
Newcastle Nov 2015 12 N/A N/A 6 0.3
Dundee Mar 2016 8 N/A N/A 4 0.2
Hull Dec 2015 15 N/A N/A 12 0.7
Romford Aug 2016 9 N/A N/A 6 0.4
Cardiff Sept 2017 11 N/A N/A 1 0.1
RLH Mar 2017 6 N/A N/A 11 1
SGH Feb 2016 26 N/A N/A 7 1.75*
Oxford Oct 2017 8 N/A N/A 3 1.5
Total (per site) 189 exc. lead (9 per site) 100
15.5 (2.2 
per site) 594
25.4 (1.2 
per site)
Table 5. Site opening timetable and recruitment in order of site openings. *top 5 recruiting sites from 
substantive trial. (exc. = excluding, pts = patients, R + D = Research and development, ST = substantive trial).
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amendments as detailed below. The National Institute for Health Research (NIHR) health technology assessment 
(HTA) programme subsequently approve progression into the substantive trial.
Changes to substantive trial protocol based upon the pilot. Eligibility changes. One major change 
occurred to the exclusion criteria following completion of the pilot trial; from “patients who are already on ster-
oids” to “patients who are on (or within one month of) regular oral or IV steroids”. The term “regular” was 
added because we noted that in some centres patients are given one dose of intra-operative dexamethasone for 
anti-emesis. This long-standing practice involves a one-off dose too small to have any significant impact on out-
come. Nevertheless, it was agreed to collect all data on single-use steroids as a concomitant medication. The route 
“oral or IV” was added to clarify that patients on inhaled steroids for conditions such as asthma could be included, 
and a 1-month washout period of recent steroid use was also stated.
Outcome measures and follow-up. The pilot trial identified that remote collection of the mRS led to several data 
errors due to incorrect completion of this part of the questionnaire by patients or blinded assessors. The complex 
order of instructions led to essential questions being missed, meaning the final mRS could not be calculated 
without repeat patient assessment. To rectify this, the questionnaire and instructions were simplified and an adju-
dication process implemented where all responses were immediately reviewed by a blinded clinician in the study 
team, to ensure timely calculation of the mRS. Set dates for completion of questionnaires were also amended to 
“windows” of acceptability to minimise protocol violations and allow patients a wide opportunity to respond 
(Table 3).
The increase in missing data at three months (Table 7) was reviewed and identified to relate to the follow-up 
process performed by a central trial administrator. At the sponsor site only, the local research nurse (RN) 
performed follow-up and had better follow-up rates due to more timely posting of questionnaires and regu-
lar follow-up phone calls to the patient, NOK and/or GP where necessary. Therefore, it was determined that 
follow-up could be maximised if the sponsor site RN performed follow-up for all sites.
Figure 5. blinded mRS scores from pre-morbid state to final 6-month outcome for all data entered on pilot 
patients at interim analysis on 5th Dec 2016. X-axis; outcome time-point, Y-axis; percentage of patients. The 
colours represent mRS scores as per the key.
Figure 4. Recruitment curve. Orange line = original planned recruitment curve, Green line = same original 
recruitment curve pushed back 5 moths due to delay start. Blue line = actual recruitment.
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Changes to secondary outcome measures. Review of the secondary outcomes showed a paucity of data from 
discharge and follow-up MoCA scores . As this assessment must be done face-to-face, it was missed if patients 
were discharged over the weekend or with little notice. It could also not be performed during remote follow-up 
and very few patients attended clinic. Therefore, it was deemed that the most pragmatic solution was to remove 
the MoCA from the substantive trial (Table 3).
Changes to safety processes. As a result of three inadvertent administrations of ward stock dexamethasone rather 
than blinded trial medication, patient trial bracelets were introduced for the substantive trial. These clearly state 
that the patient is prescribed a trial medication and must not receive ward stock dexamethasone. As identity 
wristbands must be checked before giving any medication we expected these to deter inadvertent ward dexa-
methasone use.
Initially all SAEs were collected throughout the 6-month follow-up period, however all SAEs occurring more 
than 30 days after randomisation were considered to be unrelated to the study medication and more often related 
to further falls, which are common in this patient group. Limiting SAE collection to the first 30 days is in-keeping 
with other CSDH studies and avoids unnecessary additional patient contact, given that the 3-month and 6-month 
follow-up is done remotely3.
All Patients 
screened (n)
Average screened 
per month (n)
Patients 
recruited (n)
Recruitment rate 
(%)
Cambridge 126 14 75 60%
Plymouth 25 4 5 20%
Imperial 9 2 2 22%
Southampton 43 11 13 30%
Middlesbrough 5 2.5 2 40%
Sheffield 2 2 2 100%
Birmingham 4 4 1 25%
Total: 214 (6/site) 100 47%
Table 6. Screening and recruitment rates at pilot sites.
To end of pilot 
recruitment (09-05-16)
To end of pilot follow-
up period (09-11-16)
3-month 
outcome
6-month 
outcome
3-month 
outcome
6-month 
outcome
Patients: n 55 31 165 100
Data received: n (%) 51 (93%) 30 (97%) 143 (87%) 98 (98%)
Withdrawn: n (%) 1 (2%) 1 (3%) 4 (2%) 2 (2%)
TM or LTFU: n (%) 3 (5%) 0 18 (11%) 0
Table 7. Results of data collection during pilot. (LFTU = Lost To Follow-Up, TM = transiently missing; 
applicable to patients who miss 3-month outcome).
SAEs in pilot patients AESI’s in pilot patients
Total no. of events: 11 events in 10 patients 12 events in 12 patients
Total no. of patients: 10/100 12/100
Event Terms: 2 Scalp lacerations
7 Hyperglycaemia requiring 
treatment or stopping of trial 
medication
2 Acute subdural haematomas 3 Gastric reflux
1 General physical health 
deterioration 1 New onset diabetes
1 Deep Vein Thrombosis 1 Hallucinations
1 Aspiration bronchopneumonia
1 Urinary Tract Infection
1 Fracture left Hip
1 Stroke
1 Bowel perforation secondary to 
Diverticulitis
Table 8. Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) reported during pilot.
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Addition of exploratory outcome measures. The original outcome measures were all clinically relevant, but none 
addressed the mechanistic actions of dexamethasone. The TSC agreed that exploratory outcome measures would 
be useful to aid scientific understanding of how dexamethasone works in CSDH, supporting its clinical applica-
tion and helping direct future studies on alternative CSDH pharmacotherapies.
The first exploratory objective was to assess the biological action of dexamethasone by analysing 
intra-operative and post-operative blood and CSDH fluid samples; excluding patients with active malignancy or 
immunosuppressive therapy. A range of inflammatory markers involved in CSDH pathophysiology have already 
been identified34–37. We planned to measure a panel of these markers, assessing their response to dexamethasone 
exposure in trial patients and whether this related to the recurrence rate.
Dexamethasone is also well known to reduce cerebral oedema, a feature which has not previously been investi-
gated in CSDH38,39. Cerebral oedema can occur due to fluid leaking through the blood-brain-barrier and has been 
linked to blood flow patterns in the brain (cerebral perfusion)40–42. There is some evidence that cerebral perfusion is 
globally reduced in CSDH and improves following surgical treatment43–46. Therefore, the second exploratory objec-
tive was to assess the role of dexamethasone in cerebral perfusion and oedema, utilising transcranial Doppler and 
magnetic resonance imaging (excluding patients with renal dysfunction or a pacemaker/metal implant).
Discussion
Multicentre trials often do not meet their original target recruitment in time and must be extended47. In fact, our 
average recruitment of 2.2 patients/month per site during the pilot trial exceeded the target of 2 patients/month 
per site. The target was far exceeded in two of the sites (8/month in Cambridge and 3.3/month in Southampton), 
and was below the target in the remaining five sites. Of these five sites, two are small centres (Plymouth and 
Imperial) with limited populations to recruit from and the remaining three had only been open two months. 
Overall, we considered that our target recruitment plan from the pilot could be applied to the substantive trial, but 
that we would attempt to open larger centres first and implement techniques to promote recruitment at the lowest 
recruiting sites. Three of the seven pilot sites have gone on to be in the top five recruiting sites in terms of monthly 
recruitment rate for the whole trial (Table 5). This may mean that we were successful in identifying strong sites to 
open during the pilot period, or that the longer sites are open the better they are at recruiting.
Recruitment patterns from individual centres should be carefully observed when assessing recruitment feasi-
bility with a pilot trial. As despite recruitment curves traditionally being exponential in design, this often does not 
reflect the realities of trial recruitment, which after an initial take-off can remain constant. Recruitment fatigue 
can also mean that previously well-recruiting centres may decline over the course of the years it takes to complete 
a large trial. Indeed, many of the sites we recruited after the pilot phase are recruiting less well than those opened 
during the pilot phase and recruiting rates in the top centres have remained stable or declined (Table 5). Overall 
the recruitment has declined from an average of 2.2 patients per site per month to 1.2, resulting in recruitment 
falling behind target in the substantive trial despite exceeding the pilot target (Fig. 4).
An average R + D set-up time of 5.7 months during the pilot meant that most sites opened later than antic-
ipated and only two sites were open for the first six months of the pilot (Table 5). This led to a bias in the pilot 
recruitment with 75% of the patients recruited from the lead site (Cambridge) and only 25% from other sites. This 
could affect the generalisability of the trial. To address this, recruitment is continually encouraged at other sites 
and the TSC specified that the final trial should not have more than 50% of the patients recruited from a single 
site. Currently 37% of patients have been recruited from the lead site.
The top two recruiting pilot sites were also the sites screening the largest number of patients (11–14 per site 
per month), whilst other sites only screened 2–4 patients per month. This may relate to the staffing at these sites, 
as both have a research fellow and nurse dedicated to trials. This enables them to invest more time and effort in 
identifying, approaching and discussing the trial with potential patients. Most other centres are reliant on the 
clinical staff to screen and enrol patients, adding to their daily workload and therefore requiring significantly 
more motivation. It is also highly dependent on the availability and support from the local RN, who may not have 
a neuroscience affiliation. It is self-evident that limited infrastructure and research staffing will have an impact 
on the delivery of RCTs.
A recent review on strategies to improve recruitment to RCTs suggested that only open-label studies and 
telephone reminders have been shown to increase recruitment47. As neither of these strategies were appropriate 
for this blinded trial in an acute neurosurgical population, we considered that efforts would be best directed 
towards promoting site engagement and incentivising investigators at each site to screen and enrol patients. This 
included setting up a trial website; regular newsletters to all sites highlighting trials news with local and national 
recruitment rates; trial posters for use in clinical areas to remind clinicians about the trial; additional site visits for 
training; promotion of the trial at national meetings and finally an annual investigators day. Feedback from this 
latter initiative has been very positive and is perceived to significantly impact on site engagement.
Screening failures were reviewed to assess recruitment and any potential bias in patient selection. The most 
common reason for screening failure was patient or NOK declining. Aside from ensuring local teams are well 
trained in giving correct and detailed trial information, this is an acceptable and expected reason for screen-
ing failure. The second most common reason was patient co-morbidity and it became apparent from discus-
sion with sites that there was variation in the assessment of this. For example, some sites were reporting general 
“frailty” as a common cause of exclusion, whilst other sites would be more inclusive of patients with wide ranging 
co-morbidities and medications. Clinical judgement is clearly required during the screening process but this does 
also mean that the clinicians own bias will be introduced. Indeed, it is recognised that elderly patients can be per-
ceived by clinicians as being vulnerable and needing “protection from researchers”, despite their desire to engage 
in trials17. We specifically tried to be as pragmatic and inclusive as possible when designing the eligibility criteria, 
so that the trial results will be widely applicable to the elderly population affected by CSDH. We have found regu-
lar dissemination of the trial progress and low adverse event rate has helped encourage this.
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In 8% of screening failures the patient was deemed to lack capacity and there was no available NOK. Patients 
lacking capacity are usually those with more severe CSDHs resulting in cognitive deficits. To avoid skewing the 
recruitment towards the CSDH patients with milder symptoms, IHP consent can be used when patients lack 
capacity. The pilot highlighted the need to promote this and train sites about appropriate use of IHP consent. 
There is evidence from a public opinion survey on patient inclusion in severe traumatic brain injury (TBI) clinical 
trials that 91% of respondents would be happy for an independent doctor to assent48. Despite this, we have found 
there is persistent institutional reluctance to use such proxy consent processes, which is only likely to be overcome 
by continued adoption into trials where appropriate.
The reliability of trial outcome measure collection was monitored during the pilot leading to a minor amend-
ment to the mRS questionnaire, which had been incomplete in some cases. Primary outcome data was collected 
in 97% of patients at the end of pilot recruitment period and was maintained at 98% once all pilot patients had 
reached six months, with only two patients withdrawn. The internal pilot has provided a realistic estimate of 
retention and follow-up which has been maintained into the substantive trial. It also reflects effective trial design 
with regard to strategies to maintain patients in the trial. This includes the techniques discussed in Table 2, par-
ticularly ensuring that follow-up was remote, as elderly patients are more likely to participate if follow-up is done 
from home49. A review of strategies to improve retention in randomised trials also showed that financial incen-
tives improve return of postal and electronic questionnaires, however this was not considered appropriate in an 
NHS setting50. While postal reminders have been reported to have no significant effect on follow-up, we found 
telephone follow-up reminders very helpful50. This may be specific to elderly patients who will have a higher rate 
of cognitive and physical impairments that make filling in and returning a written questionnaire difficult. Some 
patients reported preferring to answer the questionnaires over the phone.
The follow-up rate has remained excellent into the substantive trial, despite the number of trial sites increasing 
to 21 and extending from England into Scotland and Wales. The follow-up is now undertaken by the sponsor site 
RN, who dedicates a lot of time to liaising with local hospitals, GPs, patients and their NOKs to get the outcome 
data. A 6-month lost-to-follow-up (LTFU) rate of 0% in the pilot is exceptional and can only hope to be main-
tained throughout the substantive trial, however less than 5% LTFU is suggested to be acceptable in minimising 
bias to trial results51.
The pooled primary outcome (6-month mRS) was found to be favourable in 83% of pilot patients, which was 
close to that predicted for the control group for the sample size calculation (80–85%). As the aim of the pilot was 
not to assess efficacy or calculate sample size, no further analysis was done at this stage. An interim analysis with a 
sample size calculation once approximately 500 patients have reached their primary outcome is planned. This will 
permit us to make any sample size adjustments if we are close to seeing a significant treatment effect.
We anticipated a relatively high SAE rate in a trial on elderly patients with a surgical condition. This was 10% 
in the pilot and has remained at a comparable rate of 13% in the substantive trial to date. None of the SAEs in the 
pilot were considered related to the trial medication and all were events that might be expected in this cohort. 
Data was also collected on AESIs which were reported in 12% of pilot patients. Interestingly, the cumulative AESI 
rate in the most recent safety report from July 2018 is only 7% (including pilot and substantive trial data). This 
highlights the risks of collecting data in a small portion of patients such as a pilot which can have implications on 
subsequent trial conduct.
The IDMEC reviewed unblinded data on SAEs, AESIs and outcomes reported during the pilot, and had no 
safety or ethical concerns, recommending continuation onto the substantive trial with the same protocol.
Conclusion
The Dex-CSDH pilot trial demonstrated feasible recruitment, with an excellent follow-up rate and no safety 
concerns. This supported transition into an on-going substantive trial with only minor trial amendments aimed 
at improving data collection, streamlining safety processes and promoting recruitment. These changes, alongside 
the addition of exploratory outcomes, add value and scope to this important clinical trial.
Pilot trials are useful to assess feasibility and guide conduct of the subsequent substantive trial. Careful anal-
ysis of both screening and recruitment patterns permits predictable estimation of multi-centre trial recruitment 
and sharing data from pilot experiences can help guide future pilot and substantive trial design.
Data Availability
The data reported in this manuscript was analysed for internal reporting to the TSC and IDMEC and is available 
from the trial management group on reasonable request. On completion of the substantive trial, all data will be 
deposited in the University of Cambridge repository.
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